CanBas Co

CanBas Co EBITDA per Employee

The EBITDA per Employee of CanBas Co (4575.T) as of Oct 19, 2026 is -113.21 M JPY. In the previous year, EBITDA per Employee was -92.42 M JPY — a change of 22.49% (lower).

EBITDA per Employee

-113.21 MJPY

YoY

22.49%

Last updated:

EBITDA per Employee of CanBas Co is 2026 -113.21 M JPY. EBITDA per Employee of CanBas Co was 2025 -92.42 M JPY. It decreases by 22.49% lower compared to the previous year.

The CanBas Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-44.42 M JPY
Jan 1, 2020
-47.20 M JPY
Jan 1, 2021
-45.58 M JPY
Jan 1, 2022
-70.54 M JPY
Jan 1, 2023
-80.50 M JPY
Jan 1, 2024
-105.17 M JPY
Jan 1, 2025
-92.42 M JPY
Jan 1, 2026
-113.21 M JPY
The CanBas Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-113.21 MJPY+22.49%
-92.42 MJPY-12.12%
-105.17 MJPY+30.65%
-80.50 MJPY+14.12%
-70.54 MJPY+54.74%
-45.58 MJPY-3.43%
-47.20 MJPY+6.25%
-44.42 MJPY-1.18%
-44.95 MJPY+34.83%
-33.34 MJPY+3.17%
-32.32 MJPY+43.13%
-22.58 MJPY-42.14%
-39.03 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

EBITDA per Employee of CanBas Co is -113.21 M JPY in 2026.

EBITDA per Employee of CanBas Co changed from -92.42 M JPY to -113.21 M JPY, representing a 22.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee CanBas Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — CanBas Co

All Key Metrics — CanBas Co